步履不停,严谨设计推动科学探索 RATIONALE-306研究(NCT03783442)是一项具有里程碑意义的研究,研究旨在评估替雷利珠单抗联合化疗对比安慰剂联合化疗作为ESCC一线治疗的疗效和安全性。研究结果显示,替雷利珠单抗联合化疗的中位总生存期(OS)达17.2...
RATIONALE-306 (NCT03783442) assessed the efficacy and safety of tislelizumab plus investigator-chosen chemotherapy (ICC), compared with placebo plus ICC, as a first-line treatment for metastatic or unresectable ESCC [10]. At the primary analysis of RATIONALE-306, patients in the intent-to-trea...
) + CT demonstrated significant overall survival (OS) benefit vs PBO + CT as first-line (1L) therapy for advanced ESCC in all randomized patients (pts; stratified HR 0.66) and pts with PD-L1 Tumor Area Positivity (TAP) score ≥10% (stratified HR 0.62) (RATIONALE-306; NCT03783442). ...